Wilms Tumor in Sub-Saharan Africa: Molecular and Social Determinants of a Global Pediatric Health Disparity

Annie Apple¹* and Harold N. Lovvorn III²

¹ Vanderbilt University School of Medicine, Nashville, TN, United States, ² Department of Pediatric Surgery, Monroe Carrell Jr. Children’s Hospital, Vanderbilt University Medical Center, Nashville, TN, United States

Wilms tumor (WT) is the most common renal malignancy of childhood. Global disparities in WT have been reported with the highest incidence and lowest overall survival occurring in sub-Saharan African nations. After a detailed search of PubMed, we reviewed available literature on WT in sub-Saharan Africa and summarized findings that explore biologic and social factors contributing to this alarming cancer health disparity. Access to care and treatment abandonment are the most frequently reported factors associated with decreased outcomes. Implementation of multidisciplinary teams, collaborative networks, and financial support has improved overall survival in some nations. However, treatment abandonment remains a challenge. In high-income countries globally, WT therapy now is risk-stratified according to biology and histology. To a significantly lesser extent, biologic features have been studied only recently in sub-Saharan African WT, yet unique molecular and genetic signatures, including congenital anomaly-associated syndromes and biomarkers associated with treatment-resistance and poor prognosis have been identified. Together, challenges with access to and delivery of health care in addition to adverse biologic features likely contribute to increased burden of disease in sub-Saharan African children having WT. Publications on biologic features of WT that inform treatment stratification and personalized therapy in resource-limited regions of sub-Saharan Africa have lagged in comparison to publications that discuss social determinants of health. Further efforts to understand both WT biology and social factors relevant to appropriate treatment delivery should be prioritized in order to reduce health disparities for children residing in resource-limited areas of sub-Saharan Africa battling this lethal childhood cancer.

Keywords: Wilms tumor, sub-Saharan Africa, health disparity, molecular features, social determinants of health

INTRODUCTION

Wilms tumor (WT) is the most common renal malignancy of childhood. Black children of sub-Saharan African ancestry consistently show the highest incidence of WT worldwide at 11 cases per million (1). In sub-Saharan Africa, WT is reported as the second or third most common pediatric malignancy, which differs from its North American incidence (2). With the advent of cooperative
trials, multimodal treatment regimens, and multidisciplinary care models, overall survival at 5-years for patients with WT in developed nations is now greater than 90% (3). However, alarming disparities in outcomes persist for children with WT residing in sub-Saharan African nations, with overall survival at 5-years as low as 25% (4). Over the past 50 years, basic descriptions of WT prevalence, treatment challenges, and poor outcomes for children living in resource-limited settings of sub-Saharan Africa have been published, with the principal focus in more recent years on social determinants of health as contributing factors to this profound cancer disparity (2, 5–7). Only in the last decade has examination of WT biology as a molecular determinant of health in these austere contexts begun to gain momentum (8–11). The principal purposes of this review were to provide a comprehensive summary of existing literature on WT in sub-Saharan Africans and to describe the current epidemiology, biologic features, treatment strategies, and outcomes in these at-risk and vulnerable children. Further, we aimed to highlight areas of study where additional clinical and molecular research are needed.

METHODS

Publications related to WT and sub-Saharan Africa were included in this review. Using PubMed, the search terms “Wilms tumor” and “Africa” retrieved 192 results. Publications were reviewed for relevance and content by both authors and were included if WT in sub-Saharan African nations or Black populations was described. Key findings and results were abstracted from each paper and summarized. Publications were categorized as (1): biologic or molecular determinants of health, if content included description of clinical and molecular or genomic features of WT in a sub-Saharan African or Black population, or (2) social determinants of health, if content included description of access to care, treatment abandonment, cultural beliefs, or healthcare infrastructure. Date of publication and country of origin were also recorded.

RESULTS

Molecular Determinants of Health

Previous work has shown evidence of a biologic predisposition that may underlie an increased incidence of WT in children of Black sub-Saharan African descent (1). Specifically, a foundational study in 1984 showed that Black children living in the Greater Delaware Valley of the United States (i.e., Philadelphia, PA) were more likely to have congenital anomalies and syndromes associated with the development of WT. Specifically, a larger proportion of Black children had a WT-associated congenital anomaly, including aniridia, genitourinary anomalies, Beckwith-Wiedemann Syndrome, and hemihypertrophy. Although not sequenced at the time of that seminal report, these developmental conditions associating with WT predisposition now have been attributed to alterations principally in two genes, WT1 (11p13) and WT2 (11p15.5) (12–14). Among younger patients, these authors reported a greater tendency for Black children to develop bilateral WT or to carry a tumor-associated anomaly. These features suggested a hereditary predisposition towards WT among Black children or less likely a greater susceptibility to toxins that induce germline mutations in these genes (15). After development and implementation of the National Wilms Tumor Study Group (NWTS) in 1969, which yielded 5 cooperative trials to optimize WT therapy, marked improvements in overall survival with reductions in treatment toxicity have since been realized (16–18). Moreover, a once significantly disparate survival gap for Black patients has now closed, at least in North America (3). However, Black populations globally continue to show greater frequencies to develop WT and to experience alarmingly poor survival in resource-constrained nations of sub-Saharan Africa. It was proposed in 1993 that, while global frequencies of WT were stable and not linked clearly or reproducibly with parental exposures to toxins, racial heredity and ancestry were greater determinants for development of WT than environmental exposures (1). To explore this concept of greater predisposition to develop WT among Black populations and potentially to harbor more treatment-resistant disease, both epidemiologic and somatic molecular differences between Black and White patients residing in Tennessee were explored. In Tennessee, Black children also appeared more susceptible than Whites to develop WT, and imaging mass spectrometry indeed identified peptide spectra from WT blastema and stroma that suggested race-specific molecular profiles (10).

Among sub-Saharan African populations, several initial studies described molecular features of WT that suggest a unique treatment-resistant and aggressive biology. These early studies aimed to quantify the frequency of p53 mutations that notoriously associate with diffuse anaplasia and more treatment-resistant disease. In one series of WT from Kenya, higher frequencies of p53 mutation were observed in comparison to White populations, and in accordance with previous literature, expression of p53 was associated with shorter survival period and unfavorable histology (19, 20). Additional molecular markers including E-cadherin, cadherin-11, alpha, beta and gamma-catenin were also studied within an African cohort. However, expression of these molecules did not show association with prognosis (21). Through multiple collaborations in Kenya and support from the Children’s Oncology Group, disparate molecular profiles were explored between North American and Kenyan WT specimens (8, 9, 11). An unbiased proteomic screen revealed unique protein signatures between North American Black, White, and Kenyan Wilms tumor specimens with excellent and race-specific clustering. Interestingly, peptide signatures from the North American WT specimens of Black and White patients appeared more similar than those between Black North American and Kenyan patients, which suggested a unique biologic composition within this latter sub-Saharan African population and likely greater genetic admixture in the former (11). Furthermore, sequencing of the top 10 winner
peptides that associated with WT specimens from different race groups identified several interesting proteins and a novel association of Kenyan specimens with Fragile-X Related Protein – 1 (FXR1), which was subsequently characterized (22). FXR1 expression appeared to associate with undifferentiated cell types, specifically blastema, and may represent a pathway for cellular self-renewal hijacked from development (22). In Kenyan WT specimens, therefore, it is speculated that FXR1 emerged from the often blastemal-predominant cellular compartment in these cases that were analyzed commonly after neoadjuvant therapy and may represent a pathway for treatment resistance. Blastemal persistence after neoadjuvant therapy has been shown to be a poor prognostic feature, and indeed FXR1 has aligned with worse outcomes in several adult cancers (23).

Kenyan WT specimens have also been evaluated for histologic features and genomic alterations associated with somatic treatment resistance patterns. Specifically, Kenyan WT were analyzed for presence of diffuse anaplasia, which is an ominous harbinger of treatment resistance and failure, and in the majority of cases, is associated with alteration and mutation in TP53. While DAWT only comprises 5–8% of WT patients in high-income countries, anaplasia was present in 13% of Kenyan WT patients (9). Furthermore, an increased frequency of genetic and chromosomal alterations were uncovered in these specimens that have been associated with poor prognosis in high-income countries, including frequent mutations in p53, beta-catenin, and MYCN, loss of heterozygosity at 17p (which covers TP53) and 11q, and copy number gain at 1q (8, 9).

Social Determinants of Health

Differences in access to care, cultural attitudes and beliefs, infrastructure, and health care delivery mechanisms only exacerbate the dismal outcomes for children having biologic features of treatment-resistant WT and residing in sub-Saharan Africa. Loss to follow up and treatment abandonment remain the most commonly reported social challenges that contribute to treatment failure across the continent (24, 25). Studies from multiple countries have aimed to implement multidisciplinary treatment models and standardized therapy to improve outcomes. Risk factors and challenges for providing optimal treatments have been described by treatment center and country (24, 25).

In the Collaborative Wilms Tumor Project, an adapted WT treatment guideline was implemented in multiple centers across sub-Saharan Africa, including the countries of Malawi, Cameroon, Ethiopia, Uganda and Ghana. The principal aim was to decrease abandonment of treatment and to improve outcomes (26). Using this multi-center regional collaborative network, program implementation was associated with significantly higher survival without evidence of disease at the end of treatment compared to baseline evaluations (68.5% vs. 52%) (26–28). Financial support for medical treatment was highlighted as a key strategy to decrease abandonment of treatment (28). In the first multicenter prospective study in sub-Saharan Africa, seven units participated from Senegal, Madagascar, Cameroon, Cote d’Ivoire, Mali, Togo, and Burkina Faso. After protocolized treatment of unilateral, localized, standard-risk WT, a three-year overall survival rate of 73% was observed (29). However, fifteen percent of the patients did not receive optimal treatment, and principal barriers included limited access to care. Specifically, decreased availability of pathology reports, decreased availability of chemotherapeutic drugs, and lack of access to radiotherapy were described (29).

In Kenya, we reported recently a 2-year event-free survival from WT as 52.7%, which rose from 35% from prior publications. However, loss to follow up in our series was 50%, which tempered enthusiasm (24). Other studies have reported similar rates of loss to follow up at 42%. Also reported, late presentations of WT with advanced stages of disease contribute to decreased overall survival (30, 31). For those who completed standard therapy, however, 2-year event free survival has been documented as high as 94%, in accordance with overall survival in high-income nations. Insurance status and enrollment in the Kenyan National Hospital Insurance Fund (NHIF) was associated with lower hazard of death, which suggests the importance of health insurance (24). Risk factors for treatment abandonment in Kenya include financial constraints, lack of education about WT and necessity to complete treatment, and lack of drug availability (24, 25).

In Nigeria, clinical characteristics and outcomes have also been evaluated, showing larger than average tumor size at presentation in comparison to Caucasian children in high-income nations. A high mortality rate due to late clinical presentation, poor availability of chemotherapeutic agents, and inadequate follow up and treatment completion have been documented (32). Later studies evaluated outcomes following introduction of multidisciplinary team management and patient treatment stratification according to tumor histology. In this population, one third of patients were lost to follow up. Among patients who completed chemotherapy treatment, 5-year overall survival was 73.7%, but overall 5-year survival (abandonment-sensitive survival) remained low at 35.6% Barriers to care included public health measures that allowed early diagnosis, improvement of facilities, and adequate healthcare funding to receive standard therapy (33). Additional studies advocate for the need for additional health information and collaboration with institutions in high-income countries (34).

In Rwanda, nephroblastoma, or WT, was reported as the most common childhood cancer. Significant challenges to survival include unaffordable treatment, late presentation, and lack of trained staff and multidisciplinary collaboration. Recommendations for improvement again highlight improvement in patient education, free health care for children with cancer, international partnerships with tertiary care centers (35).

In Malawi, presentation at advanced stage and high recurrence rates are reported even with completion of therapy at 15% (36). An adapted WT treatment guideline and strategies to enable children to complete treatment were introduced. Two- and five-year event-free survivals remained decreased at 46 and 42%, respectively, in comparison to high income countries, and causes of treatment failure included abandonment of care for 7%
of children, 15% with death during treatment, and 30% with disease-related deaths. Suggestions to optimize WT management in Malawi included strengthening social support programs, treatment compliance, nutrition, and modifications to reduce treatment-related deaths (37).

In South Africa, nutritional status was highlighted as a further prognostic feature impacting outcome from WT. Prevalence of malnutrition was as high as 66% using combined laboratory and anthropometric data. For this reason, early aggressive nutritional resuscitation for malnourished children in marginalized sub-Saharan African countries and populations was recommended (38). While presentation with advanced disease remained a challenge, treatment by multidisciplinary teams in Johannesburg showed improved survival outcomes relative to other sub-Saharan African nations (39). Furthermore, an additional study in South Africa showed that when treatment protocols employed in the United States were implemented in this African setting with robust surgical care, estimated 5-year overall survival was 94.4% (40).

The combined results of these publications from populations across sub-Saharan Africa highlight the need for improved access to care, availability of standard therapy for WT, supportive care, and patient education. These challenges remain significant and are cited as the primary determinant of decreased overall survival from WT in Africa in comparison to high-income nations (6, 7, 41, 42). Altogether, marginalized access to less than adequate therapies for malnourished children having advanced stage, treatment-resistant WT is exceedingly difficult to overcome, hence the horrific yet consistently poor survival in certain areas of sub-Saharan Africa.

**Timeline and Categorization of Publications**

A total of 26 papers were included in this review. Since the first included publication in 1984, a total of 19 papers described social determinants of health and the impact of various financial, cultural, and structural barriers to optimal treatment in African populations on survival from WT (Table 1). Significant improvements have been made to address these barriers, including collaborative clinical trials, implementation of treatment protocols, multidisciplinary teams, international partnerships, and unique strategies for increasing access to care. Since the first publication in 1984, a total of 7 papers described molecular and genomic features within WT of sub-Saharan Africa (Table 1). A timeline underscores the lag to investigate molecular features for more optimal risk stratification and treatment assignment (Figure 1).

**DISCUSSION**

WT disproportionately impacts Black children residing in sub-Saharan Africa and worldwide. This review illustrates significant progress in characterizing the clinical and molecular features of WT in sub-Saharan Africa and improving outcomes over the last 50 years, but clearly much work remains. Most sub-Saharan African nations categorized as low to middle income have seen improvement in survival outcomes since initial reports 4 decades ago, albeit not consistently near results from high income countries. Treatment abandonment remains a significant challenge reported by authors from multiple sub-Saharan African countries. The primary focus of research on WT in resource-limited regions of Africa is necessarily devoted to social determinants of health and decreasing barriers to care, of which there are many. Improving patient outcomes requires decreasing delayed presentation and diagnosis, increasing collaboration between interdisciplinary teams, improving access to pathology for treatment stratification, increasing availability of surgery, radiation, and chemotherapeutic agents, increasing adherence with follow up care, and comprehensive survivorship clinics. All of these factors are also likely impacted by finances, health literacy, and cultural beliefs. While these social determinants are certainly present in developed nations, it appears these inequities are exacerbated in low-resource settings of sub-Saharan Africa.

With the advent of targeted therapies, new frontiers of oncologic care focus on characterizing molecular signatures of disease with the goal of providing pathway- and cell-specific, personalized treatments. In high income nations, the focus of most WT research is optimizing therapy through further study of biomarkers associated with aggressive and treatment-resistance disease. This strategy to incorporate biologic features that assign risk of treatment failure within therapeutic regimens affords patients harboring a predictably sensitive WT to be exposed to less toxic therapy (4). The corollary of patients having a biologically high-risk WT will be assigned more appropriately intensive therapies. For example, specific genetic features of WT, including LOH for alleles spanning chromosomes 1p and 16q, are biomarkers that, when both present, associate with increased risk of relapse and death and have implications for more intensive management. Identifying additional prognostic biomarkers is an active area of study (43). Currently, the understanding of the genetic features of WT are based on specimens almost exclusively from patients in developed nations, which may not be generalizable to sub-Saharan African WT. Previous work has shown evidence of a predisposition among Black populations of sub-Saharan African ancestry to develop WT and that molecular markers associated with poor prognosis and treatment-resistant disease may well confound standard therapies. Further study and inclusion of African patients in molecular and genetic research is required to equitably advance treatment options for all patients with WT globally. Improved understanding of biologic features of WT in African populations will allow for risk stratification in parallel to the use of Children’s Oncology Group (COG) and International Society of Pediatric Oncology (SIOP) treatment protocols. Advancement of personalized therapies for WT in Africa will require collaborative efforts to characterize molecular features, determine prognostic significance, and evaluate the efficacy of tailoring chemotherapy intensity accordingly.

Limitations of this review include the incorporation of only published work and lack of sub-Saharan collaborators. The data...
TABLE 1 | Publications on Wilms tumor among sub-Saharan Africans.

| Author            | Journal/Date              | Title                                                                 | Country(ies) | Findings                                      |
|-------------------|---------------------------|-----------------------------------------------------------------------|---------------|-----------------------------------------------|
| Kyambi et al.     | East African Medical Journal/1981 | The management of Wilms tumor in Kenya                                | Kenya         | Late presentation and Loss to follow up (LTFU) |
| Kramer et al.     | Medical and Pediatric Oncology/1984 | Racial Variation in incidence of Wilms tumor: relationship to congenital anomalies | United States | Genetic                                       |
| Breslow et al.    | Medical and Pediatric Oncology/1993 | Epidemiology of Wilms Tumor                                            | Global        | Genetic                                       |
| Wessels et al.    | Pediatric Hematology Oncology/1999 | Nutrition, morbidity, and survival in South African children with Wilms’ tumor | South Africa  | Malnutrition                                  |
| Ekenze et al.     | Annals of Oncology/2006    | The challenge of nephroblastoma in a developing country               | Nigeria       | Health education and collaboration             |
| Davidson et al.   | Pediatric Blood Cancer/2006 | Wilms tumor experience in a South African Centre                      | South Africa  | Treatment protocols and collaboration          |
| Uba and Chirdan   | West African Journal of Medicine/2007 | Wilms tumor: prognostic features in North Central Nigeria             | Nigeria       | LTFU                                          |
| Rogers et al.     | European Journal of Pediatric Surgery/2007 | Experience and outcomes of nephroblastoma in Johannesburg 1999-2003 | South Africa  | Late presentation, collaboration               |
| Israels et al.    | Pediatric Blood Cancer/2009 | Acute malnutrition is common in Malawian patients with Wilms tumor: a role for peanut butter | Malawi        | Late presentation, LTFU                       |
| Wilde et al.      | African Journal of Paediatric Surgery/2010 | Challenges and outcome of Wilms’ tumor management in a resource-constrained setting | Malawi        | Malnutrition, late presentation, LTFU, drug availability |
| Axt et al.        | Journal of Surgical Research/2011 | Race disparities in Wilms tumor incidence and biology                 | United States | Proteomic                                     |
| Tenge et al.      | East African Medical Journal/2012 | Management and outcome of patients with Wilms Tumor (nephroblastoma) at the MOI Teaching and Referral Hospital, Eldoret, Kenya | Kenya         | Late presentation, LTFU, drug availability    |
| Murphy et al.     | International Journal of Cancer/2012 | Molecular characterization of Wilms’ tumor from a resource-constrained region of sub-Saharan Africa | Kenya         | Proteomic, Histologic                         |
| Axt et al.        | Journal of Pediatric Surgery/2013 | Wilms tumor survival in Kenya                                          | Kenya         | LTFU, cost of treatment                       |
| Israels et al.    | Pediatric Hematology Oncology/2014 | Management of children with Wilms tumor in Africa and Europe; thoughts about costs, priorities and collaboration | The Netherlands and Malawi | LTFU, malnutrition, cost of treatment, collaboration |
| Israels et al.    | Pediatric Hematology Oncology/2014 | Clinical trials to improve childhood cancer care and survival in sub-Saharan Africa | Sub-Saharan Africa | LTFU, cost of treatment, collaboration |
| Libes et al.      | Journal of the American College of Surgeons/2014 | Race disparities in peptide profiles of North American and Kenyan Wilms Tumor Specimens | United States and Kenya | Proteomic |
| Libes et al.      | Pediatric Blood Cancer/2015   | Risk factors for abandonment of Wilms tumor therapy in Kenya         | Kenya         | Cost of treatment, education, drug availability |
| Paintsil et al.   | European Journal of Cancer/2015 | The Collaborative Wilms Tumor Africa Project; baseline evaluation of Wilms tumor treatment and outcome in eight institutes in sub-Saharan Africa | Malawi, Cameroon, Ghana, Ethiopia, Uganda | LTFU and death during treatment |
| Kanyamuhunga et al. | Pan African Medical Journal/2015 | Treating childhood cancer in Rwanda: the nephroblastoma example       | Rwanda        | Late presentation, cost of treatment, education, health care personnel History |
| Atanda et al.     | African Journal of Paediatric Surgery/2015 | Wilms tumor: determinants of prognosis in an African setting         | Kenya         | Genomic                                       |
| Lovvorn et al.    | Genes, Chromosomes, and Cancer/2015 | Genetic and chromosomal alterations in Kenyan Wilms Tumor              | Kenya         | Genomic                                       |
| Israels et al.    | Pediatric Blood & Cancer/2018 | Improved outcome at end of treatment in the Collaborative Wilms tumor Africa Project | Malawi, Cameroon, Ghana, Ethiopia, Uganda | Collaboration, LTFU, cost of treatment |
| Yao et al.        | Journal of Global Oncology/2019 | Treatment of Wilms Tumor in Sub-Saharan Africa: Results of the Second French African pediatric Oncology Group Study | Senegal, Madagascar, Cameroon, Cote D’Ivoire, Mali, Togo, Burkina Faso | Treatment availability |
| Ekenze et al.     | Pediatric Blood & Cancer/2019 | Continuing barriers to care of Wilms tumor in a low-income country    | Nigeria       | Late presentation, cost of treatment, health care facilities |
| Chagalu et al.    | Pediatric Blood & Cancer/2020 | Improvement of overall survival in the Collaborative Wilms Tumor Africa Project | Malawi, Cameroon, Ghanai, Ethiopia, Uganda | Collaboration, LTFU, cost of treatment |
reviewed may not reflect the entirety of research that has been conducted on Wilms Tumor in Africa, particularly studies that are ongoing or unpublished. Included publications were written by primarily sub-Saharan researchers and collaborators. However, the authors of this review do not practice in sub-Saharan Africa and therefore, may not capture additional perspectives or insights based on first-hand experience from within the region. Strengths of the review include the comprehensive summary of biologic and social factors relevant to understanding this pediatric health disparity, contemporary discussion of research trends over several decades, and suggestion of future directions to improve outcomes.

While social determinants are foundational and critical to improving outcomes for children with WT in sub-Saharan Africa, additional research is needed to better characterize disease at the genetic and molecular level. The results of this review show that publications on biologic and molecular features of disease in African WT are lagging in comparison to publications regarding social determinants of health. Sub-Saharan African children having WT are not only disproportionately impacted by structural and cultural barriers to care, but also may harbor a tumor biology that would benefit from additional risk stratification and personalized therapies. Indeed, even in high-income countries where access to appropriate care is assured, WT that acquire treatment-resistant molecular features are difficult enough to cure, let alone in resource-poor settings where social barriers abound, as described above. In order to address the persistent and widely reported health disparities in WT in Africa, efforts to address systems of care and decreasing treatment abandonment should remain a priority, in addition to improved understanding of Wilms tumorigenesis to advance personalized treatments.

**AUTHOR CONTRIBUTIONS**

HL contributed to the conception and design of the study. AA and HL contributed to the collection of the data, analysis, and manuscript development. All authors contributed to the article and approved the submitted version.

**REFERENCES**

1. Breslow N, Olshan A, Beckwith JB, Green DM. Epidemiology of Wilms tumor. *Med Pediatr Oncol* (1993) 21(3):172–81. doi: 10.1002/mpo.2950210305

2. Hadley LG, Rouma BS, Saad-Eldin Y. Challenge of pediatric oncology in Africa. *Semin Pediatr Surg* (2012) 21(2):136–41. doi: 10.1053/j.smpedsurg.2012.01.006

3. Linabery AM, Ross JA. Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975-1999. *Cancer* (2008) 113(9):2575–96. doi: 10.1002/cncr.23866

4. Cunningham ME, Klug TD, Nuchtern JG, Chintagumpala MM, Venkatramani R, Lubega J, et al. Global Disparities in Wilms Tumor. *J Surg Res* (2020) 247:34–51. doi: 10.1016/j.jss.2019.10.044

5. Kumon K, Kaneko Y. Social and biological factors influencing the outcomes of children with Wilms tumors in Kenya and other Sub-Saharan countries. *Trans Pediatr* (2014) 3(1):42–6. doi: 10.3978/j.issn.2224-4336.2014.01.08

6. Carter NH, Avery AH, Libes J, Lovvorn HN, 3rd, Hansen EN. Pediatric Solid Tumors in Resource-Constrained Settings: A Review of Available Evidence on Management, Outcomes, and Barriers to Care. *Children (Basel)* (2018) 5(11):143. doi: 10.3390/children5110143

7. Nyaguthi KM, Hansen EN. Pediatric solid tumors in Africa: different biology? *Curr Opin Pediatr* (2017) 29(3):354–7. doi: 10.1097/MOP.0000000000000483

8. Lovvorn HN, 3rd, Pierce J, Libes J, Li B, Wei Q, Correa H, et al. Genetic and chromosomal alterations in Kenyan Wilms Tumor. *Genes Chromosomes Cancer* (2015) 54(11):702–15. doi: 10.1002/gcc.22281

9. Murphy AJ, Axt JR, de Caestecker C, Pierce J, Correa H, Seeley EH, et al. Molecular characterization of Wilms’ tumor from a resource-constrained region of sub-Saharan Africa. *Int J Cancer* (2012) 131(6):E983–94. doi: 10.1002/ijc.27544

10. Axt J, Murphy AJ, Seeley EH, Martin CA, Taylor C, Pierce J, et al. Race disparities in Wilms tumor incidence and biology. *J Surg Res* (2011) 170(1):112–9. doi: 10.1016/j.jss.2011.03.011
11. Libes JM, Seeley EH, Li M, Axt JR, Pierce J, Correa H, et al. Race disparities in peptide profiles of North American and Kenyan Wilms tumor specimens. J Am Coll Surg (2014) 218(4):707–20. doi: 10.1016/j.jamcollsurg.2013.12.044

12. Koufos A, Grundy P, Morgan K, Alick KA, Hadro T, Lampkin BC, et al. Familial Wiedemann-Bekwith syndrome and a second Wilms tumor locus both map to 11p15.5. Am J Hum Genet (1989) 44(5):711–9.

13. Ping AJ, Reeve AE, Law DJ, Young MR, Bochnke M, Feinberg AP. Genetic linkage of Beckwith-Wiedemann syndrome to 11p15. Am J Hum Genet (1989) 44(5):720–3.

14. Tay JS. Molecular genetics of Wilms’ tumor. J Paediatr Child Health (1995) 31(5):379–83. doi: 10.1111/j.1440-1754.1995.tb00841.x

15. Kramer S, Meadows AT, Jarrett P. Racial variation in incidence of Wilms’ tumor: relationship to congenital anomalies. Med Pediatr Oncol (1984) 12(6):401–5. doi: 10.1002/mpo.2950120609

16. D’Angio GJ, Evans A, Breslow N, Beckwith B, Bishop H, Farewell V, et al. The treatment of Wilms’ tumor: results of the second National Wilms’ Tumor Study. Cancer (1981) 47(9):2302–11. doi: 10.1002/1097-0142(19810501)47:9<2302::AID-CNCR2820470933>3.0.CO;2-K

17. D’Angio GJ, Evans AE, Breslow N, Beckwith B, Bishop H, Feigl P, et al. The treatment of Wilms’ tumors of the results of the national Wilms’ Tumor Study. Cancer (1976) 38(2):633–46. doi: 10.1002/1097-0142(197608)38(2):633::AID-CNCR28203802033.0.CO;2-5

18. Neville HL, Ritche Y. WILMS TUMOR: Overview of National Wilms’ Tumor Study Group Results. Urologic Clinics North America (2000) 27(3):435–42. doi: 10.1016/S0094-0143(01)70091-4

19. Atanda AT, Anyanwu LI, Atanda OJ, Mohammad AM, Abdullahi LB, Farinayo AU. Wilms’ tumour: Determinants of prognosis in an African setting. Afr J Paediatr Surg (2015) 12(3):171–6. doi: 10.4103/0189-6725.170185

20. Govender D, Harilal P, Hadley GP, Chetty R. p53 protein expression in nephroblastomas: a predictor of poor prognosis. Br J Cancer (1998) 77(2):314–8. doi: 10.1038/bjc.1998.48

21. Ramburan A, Hadley G, Govender D. Expression of E-cadherin, cadherin-11, α-, β- and γ-catenins in nephroblastomas: relationship with clinicopathological parameters, prognostic factors and outcome. Pathology (2006) 38(1):39–44. doi: 10.1080/00313020500462056

22. Phelps HM, Pierce JM, Murphy AJ, Correa H, Qian J, Massion PP, et al. FRX1 expression domain in Wilms tumors. J Pediatr Surg (2019) 54(6):1198–205. doi: 10.1016/j.jpedsurg.2019.02.030

23. Qian J, Hassanein M, Hoeksema MD, Harris BK, Zou Y, Chen H, et al. The RNA binding protein FRX1 is a new driver in the 3q26-29 amplicon and predicts poor prognosis in human cancers. Proc Natl Acad Sci (2015) 112(11):3469–74. doi: 10.1073/pnas.1421975112

24. Axt J, Abdallah F, Axt M, Githanga J, Hansen E, Lessan J, et al. Wilms tumor survival in Kenya. J Pediatr Surg (2013) 48(6):1254–62. doi: 10.1016/j.jpedsurg.2013.03.021

25. Libes J, Oruko O, Abdallah F, Githanga J, Ndugu J, Musimbi J, et al. Risk factors for abandonment of Wilms tumor therapy in Kenya. Pediatr Blood Cancer (2015) 62(2):252–6. doi: 10.1002/pbc.25312

26. Israëls T, Paintsil V, Nyirenda D, Kouya F, Mbab Afungchwi G, Hesseling P, et al. Improved outcome at end of treatment in the collaborative Wilms tumour Africa project. Pediatr Blood Cancer (2018) 65(5):e26945. doi: 10.1002/pbc.26945

27. Paintsil V, David H, Kambugu J, Renner L, Kouya F, Eden T, et al. The Collaborative Wilms Tumour Africa Project; baseline evaluation of Wilms tumour treatment and outcome in eight institutes in sub-Saharan Africa. Eur J Cancer (2015) 51(1):84–91. doi: 10.1016/j.ejca.2014.10.030

28. Chagulaka G, Paintsil V, Renner L, Weijers J, Chitsike I, Borgstein E, et al. Improvement of overall survival in the Collaborative Wilms Tumour Africa Project. Pediatr Blood Cancer (2020) 67:e28383. doi: 10.1002/pbc.28383

29. Yao AJ, Moreira C, Traoré F, Kabore S, Pondy A, Rakotomahafa Narison ML, et al. Treatment of Wilms Tumor in Sub-Saharan Africa: Results of the Second French African Pediatric Oncology Group Study. J Glob Oncol (2019) 5:1–8. doi: 10.1200/jgo.18.00204

30. Tenge CN, Were PA, Aloucho LH, Wekesa JW, Patel K, Kuremu RT. Management And Outcome Of Patients With Wilms’ Tumour (Nephroblastoma) At The Moi Teaching And Referral Hospital, Eldoret, Kenya. East Afr Med J (2012) 89(4):121–7.

31. Kyamuhunga A, Tuyisenge L, Stefan DC. Treating childhood cancer in Rwanda: the nephroblastoma experience. Pan Afr Med J (2015) 21:326. doi: 10.11604/pamj.2015.21.326.5912

32. Wilde JC, Lanerus W, van Hasselt EH, Molyneux EM, Heij HA, Borgstein EG. Challenges and outcome of Wilms’ tumor management in a resource-constrained setting. Afr J Paediatr Surg (2010) 7(3):159–62. doi: 10.4103/0189-6725.70416

33. Israels T, Borgstein E, Jamal M, de Kraker J, Caron HN, Molyneux EM. Acute malnutrition is common in Malawian patients with a Wilms tumour: A role for peanut butter. Pediatr Blood Cancer (2009) 53(7):1221–6. doi: 10.1002/pbc.22158

34. Wessels G, Hesseling PB, Van Ommeren KH, Boonstra V. Nutrition, morbidity, and survival in South African children with Wilms’ tumor. Pediatr Hematol Oncol (1999) 16(4):321–7. doi: 10.1080/088801997277146

35. Rogers T, Bowley DM, Poole J, Swanepoel P, Wainwright J, Beale P, et al. Experience and outcomes of nephroblastoma in Johannesburg, 1998 - 2003. Eur J Pediatr Surg (2007) 17(1):41–4. doi: 10.1055/s-2007-964917

36. Davidson A, Hartley P, Desai F, Daubenton J, Rode H, Millar A. Wilms tumour experience in a South African centre. Pediatr Blood Cancer (2006) 46(4):465–71. doi: 10.1002/pbc.20388

37. Israels T, Bailey S, Verschoor R, Kaspers GJ, Kennedy N, Molyneux EM. Management of children with Wilms tumor in Africa and Europe; thoughts about costs, priorities and collaboration. Pediatr Hematol Oncol (2014) 31(3):395–9. doi: 10.1007/s10888-014-294611

38. Israels T, Kambugu J, Kouya F, El-Mallawany NK, Hesseling PB, Kaspers GJ, et al. Clinical trials to improve childhood cancer care and survival in sub-Saharan Africa. Nat Rev Clin Oncol (2013) 10(10):599–604. doi: 10.1038/nrclinonc.2013.137

39. Trager TD, Chowdhury T, Pritchard-Jones K, Behjati S. The genetic changes of Wilms tumor. Nat Rev Nephrol (2019) 15(4):240–51. doi: 10.1038/s41581-019-0112-0

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.